Immune-Mediated Hemolytic Anemia (IMHA): Diagnosis, Treatment, and Prognosis

Immune-mediated hemolytic anemia (IMHA) is one of the most common life-threatening causes of anemia in dogs and remains an important, though less frequent, disease in cats. In many patients, IMHA presents as a true medical emergency. Therefore, rapid recognition, accurate diagnosis, and timely intervention are essential for survival.

---

What Is Immune-Mediated Hemolytic Anemia (IMHA)?

IMHA occurs when a dog’s or cat’s immune system mistakenly targets and destroys its own red blood cells. As red blood cell destruction accelerates beyond the bone marrow’s ability to compensate, anemia develops. Consequently, oxygen delivery to tissues declines and may result in organ dysfunction or death.

Veterinarians classify IMHA into two major categories:

Non-Associative (Primary or Idiopathic) IMHA

• No identifiable underlying trigger

Associative (Secondary) IMHA

• Immune-mediated hemolysis occurs in association with:
  • Infectious disease (for example, tick-borne disease)
  • Neoplasia
  • Inflammatory or immune-mediated disorders
  • Drug exposure or immune stimulation

Importantly, identifying whether IMHA is non-associative or associative directly influences treatment selection, prognosis, and duration of immunosuppressive therapy.

---

Why Diagnosing IMHA Is Challenging

One of the most important messages from the ACVIM consensus statement is clear:

No single test definitively diagnoses IMHA in all patients.

Instead, IMHA is a clinicopathologic diagnosis that requires combining multiple findings. Over-reliance on any single test, such as a Coombs’ test alone, increases the risk of misdiagnosis.

To diagnose IMHA with confidence, veterinarians must demonstrate:

• Anemia
• Immune-mediated red blood cell destruction (hemolysis)

---

Step 1: Confirming Anemia and Hemolysis

Confirming Anemia

A complete blood count (CBC) confirms anemia. In addition, affected dogs and cats often show:

• Lethargy or weakness
• Pale mucous membranes
• Tachycardia or tachypnea
• Collapse in severe cases

Evidence of Hemolysis

Hemolysis indicates active red blood cell destruction and may present as:

• Icterus (jaundice) of the gums, sclera, or skin
• Hyperbilirubinemia on serum biochemistry
• Hemoglobinemia or hemoglobinuria

Although these findings confirm red blood cell destruction, they do not independently confirm immune-mediated disease.

---

Step 2: Demonstrating Immune-Mediated Red Blood Cell Destruction

The ACVIM consensus recommends using multiple immune-based tests whenever possible.

Saline Agglutination Testing

• Detects antibody-mediated red blood cell clumping
• A strong positive result strongly supports IMHA
• Improper technique may produce false-positive results

Direct Antiglobulin (Coombs’) Test

• Detects antibodies or complement bound to red blood cells
• A positive result supports IMHA
• A negative result does not exclude IMHA, particularly early or previously treated cases

Blood Smear Evaluation

• Spherocytes are a classic finding in dogs
• Smear review also helps rule out alternative causes of anemia, such as parasites or red blood cell fragmentation

Flow Cytometry (When Available)

• Detects immunoglobulins on red blood cell membranes
• Useful in select cases, although not widely available

Key takeaway:
The ACVIM consensus recommends identifying at least two indicators of immune-mediated red blood cell destruction, combined with evidence of hemolysis, before confidently diagnosing IMHA.

---

Why Screening for Underlying Causes Matters

Before diagnosing non-associative IMHA, clinicians should actively evaluate for secondary triggers, including:

• Infectious disease
• Neoplasia
• Inflammatory conditions
• Drug exposure

This step is critical because:

• Treating the underlying disease may reduce immune activation
• Prognosis differs between primary and secondary IMHA
• Some patients require less aggressive or shorter-term immunosuppression

For pet owners, this explains why additional testing is often recommended even after IMHA is suspected.

---

Treating Immune-Mediated Hemolytic Anemia

Immunosuppression Is the Cornerstone of Therapy

Most dogs with IMHA require immunosuppressive medications to stop ongoing red blood cell destruction. Corticosteroids, such as prednisone, form the foundation of treatment. In addition, current guidelines support adding a second immunosuppressive agent early to improve outcomes.

Common options include:

• Cyclosporine
• Mycophenolate
• Azathioprine (dogs only)
• Leflunomide

As a result, treatment often involves multiple medications, frequent monitoring, and gradual dose adjustments over weeks to months.

---

Blood Transfusions Can Be Life-Saving

Many dogs with IMHA develop severe anemia and require blood transfusions for stabilization. Importantly, the need for transfusion does not indicate treatment failure. Instead, transfusions provide essential support while immunosuppressive medications take effect.

---

Blood Clots Are a Major Risk

Dogs with IMHA are at high risk for thrombosis affecting the lungs, brain, or other vital organs. Therefore, thromboprophylaxis is a critical component of therapy.

The consensus guidelines support antithrombotic medications, such as clopidogrel, with drug selection tailored to each patient’s risk factors and clinical status.

---

Not Every Therapy Works for Every Dog

Adjunctive therapies, including intravenous immunoglobulin (IVIG), splenectomy, or therapeutic plasma exchange, may benefit select patients. However, evidence remains mixed, and these treatments are not universally recommended.

This variability highlights an essential principle: IMHA treatment must be individualized, and response to therapy varies widely.

---

What This Means for Pet Owners

Treatment for IMHA is often intensive and may require hospitalization, frequent rechecks, and long-term medication. Recovery can be slow, and relapses may occur. Nevertheless, many dogs survive and enjoy a good quality of life.

Ask your veterinarian or a board-certified specialist why specific treatments are recommended and what monitoring is required. Managing IMHA is a team effort.

---

The Bottom Line

The ACVIM consensus guidelines represent a major step forward in standardizing care for canine IMHA. By combining evidence-based medicine with expert clinical judgment, these recommendations aim to improve outcomes while acknowledging the complexity of this disease.